[Federal Register Volume 72, Number 96 (Friday, May 18, 2007)]
[Notices]
[Page 28073]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-9608]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on July 28, 2006, Cody 
Laboratories, Inc., 601 Yellowstone Avenue, Cody, Wyoming 82414, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of the basic classes of controlled 
substances listed in schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Dihydromorphine (9145).....................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Amobarbital (2125).........................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Cocaine (9041).............................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Diphenoxylate (9170).......................  II
Meperidine (9230)..........................  II
Oxymorphone (9652).........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans on manufacturing the listed controlled substance 
in bulk for sale to its customers.
    Any other such applicant, and any person who is presently 
registered with DEA to bulk manufacture such a substance, may file 
comments or objections to the issuance of the proposed registration 
pursuant to 21 CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administration, Office of Diversion Control, Federal Register 
Representative(ODL), Washington, DC 20537, or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative(ODL), 2401 
Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed 
no later than July 17, 2007.

    Dated: May 10, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-9608 Filed 5-17-07; 8:45 am]
BILLING CODE 4410-09-P